Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission - 10

Conquering CML | The Breakthrough Paradigm Change of Treatment-free Remission

References
1. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib
in patients with chronic myeloid leukemia in
chronic phase: Results from the ENEST freedom
study. Leukemia 2017;31:1525-1531.

5. Mahon F-X, Richter J, Guilhot J, et al. Cessation of
tyrosine kinase inhibitors treatment in chronic
myeloid leukemia patients with deep molecular response: Results of the Euro-Ski trial. Blood
2016;128:787.

2. Ross DM, Masszi T, Casares MTG. Durable treatment-free remission in patients with chronic
myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the
ENESTfreedom study. J Cancer Res Clin Oncol
2018; in press.

6. Saussele S, Richter J, Guilhot J, et al. "Duration
of Deep Molecular Response" Has Most Impact
on the Success of Cessation of Tyrosine Kinase
Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial. Oral Presentation at American Society of Hematology
annual meeting, December 2017, Atlanta, GA.

3. Hochhaus A, Saglio G, Hughes TP, et al. Longterm benefits and risks of frontline nilotinib
vs imatinib for chronic myeloid leukemia in
chronic phase: 5-year update of the randomized
ENESTnd trial. Leukemia 2016;30:1044-1054.
4. Hughes TP, Hochhaus A, Kim D-W, et al. Treatment-free remission (TFR) among patients with
chronic myeloid leukemia in chronic phase
(CML-CP) not initially eligible for treatment discontinuation due to unstable deep molecular
response (DMR): Enestfreedom and Enestop.
Blood 2017;130(Suppl 1):2878.
10

A Clinical OMICs eBook

9. Saussele S, Richter J, Hochhaus A, Mahon F-X. The
concept of treatment-free remission in chronic
meyloid leukemia. Leukemia 2016;30:1638-1647.
10. Elsayed AG, Srivastava R, Jamil MO. Treatment-free remission: A new therapeutic goal in
chronic myelogenous leukemia. Curr Oncol Rep
2017;19(12):77.
11. Narra RK, Flynn KE, Atallah E. Chronic myeloid
leukemia - the promise of tyrosine kinase
inhibitor discontinuation. Curr Hematol Malig
Rep 2017;12(5):415-423.

7. Takahashi N, Tauchi T, Kitamura K, et al. Deeper
molecular response is a predictive factor for
treatment-free remission after imatinib discontinuation in patients with chronic phase chronic
myeloid leukemia: the JALSG-STIM213 study. In
J Hematol 2017;doi.org/10.1007/s12185-0172334-x.

12. Annals of Internal Medicine. 2018 Feb 20. doi:
10.7326/M17-1094. [Epub ahead of print] Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid
Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

8. Hughes TP, Ross DM. Moving treatment-free
remission into mainstream clinical practice in
CML. Blood 2016;128(1):17-23.

13. Khoury HG, Williams LA, Atallah E, Hehlmann
R. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. Am Soc Clin
Oncol Educ Book 2017;37:468-479.

www.clinicalomics.com

http://www.clinicalomics.com

Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission

Table of Contents for the Digital Edition of Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission